{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00023528", "CSN": null, "TRF": "ORD_1462448_01", "MRN": "45969184", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1200868", "clinicalId": "1202238", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1462448_01", "SampleName": "US1401552.01", "Version": "0", "Sample": {"FM_Id": "ORD_1462448_01", "SampleId": "US1401552.01", "BlockId": "nan", "TRFNumber": "ORD_1462448_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_09_21", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "57", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97925", "MRN": "45969184", "FullName": "\u856d\u6f2a\u96ef", "FirstName": "I_Wen", "LastName": "Hsiao", "SubmittedDiagnosis": "Metastasic neuroendocrine carcinoma (From clinical diagnosis)", "Gender": "Female", "DOB": "1978_01_26", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_09_19", "ReceivedDate": "2022-10-12 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Neuroendocrine carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "34", "clinicalTrialCount": "35", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "P278L"}, {"geneName": "APC", "isVUS": "true", "variantName": "P1440Q"}, {"geneName": "AR", "isVUS": "true", "variantName": "D496N"}, {"geneName": "ATM", "isVUS": "true", "variantName": "D1080G,H2208Y"}, {"geneName": "BCOR", "isVUS": "true", "variantName": "V450I"}, {"geneName": "BRCA1", "isVUS": "true", "variantName": "T1675A"}, {"geneName": "C11orf30 (EMSY)", "isVUS": "true", "variantName": "P1006R"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "L1296del"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "E457del"}, {"geneName": "KEAP1", "isVUS": "true", "variantName": "M409V"}, {"geneName": "LTK", "isVUS": "true", "variantName": "C759Y"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "T426A"}, {"geneName": "NF1", "isVUS": "true", "variantName": "K1099E,L552R"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "V211M"}, {"geneName": "PIK3CA", "isVUS": "true", "variantName": "Q958R"}, {"geneName": "POLD1", "isVUS": "true", "variantName": "A692V,G237fs*39,S766P"}, {"geneName": "PTEN", "isVUS": "true", "variantName": "A39T"}, {"geneName": "REL", "isVUS": "true", "variantName": "P329L"}, {"geneName": "SMARCA4", "isVUS": "true", "variantName": "R1189L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "Q543*, Y215fs*17", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "Q543*"}, {"isEquivocal": "false", "name": "Y215fs*17"}]}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, Jan 2022) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). ARID1A protein loss is associated with tumors of poor histological grade for many tumor types, including colorectal cancer (CRC) (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809), cervical cancer (Katagiri et al., 2012; 22274316, Cho et al., 2013; 23427874), gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857), urothelial carcinoma (Gui et al., 2011; 21822268, Balbas_Martinez et al., 2013; 23650517, Faraj et al., 2014; 25175170), ovarian and endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907, Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352, Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303), breast carcinoma (Zhang et al., 2012; 21889920, Mamo et al., 2012; 21892209, Zhao et al., 2014; 24430365), and clear cell renal cell carcinoma (Lichner et al., 2013; 23416164); ARID1A mutation has been associated with poor outcomes for patients with cholangiocarcinoma (Feng et al., 2021; 33387086, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Ruzzenente et al., 2016; 26717940). However, prognostic data regarding patient survival are often mixed and conflicting. There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited preclinical evidence from studies in ovarian cancer, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009), which are under investigation in clinical trials. Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in colorectal cancer cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04657068", "Include": "true"}, {"nctId": "NCT02595931", "Include": "true"}, {"nctId": "NCT04514497", "Include": "true"}, {"nctId": "NCT04616534", "Include": "true"}, {"nctId": "NCT04802174", "Include": "true"}, {"nctId": "NCT04266912", "Include": "true"}, {"nctId": "NCT03669601", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "13", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "13"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a bTMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). In 1 retrospective study of patients with advanced neuroendocrine tumors not treated with immunotherapy, tumor mutational burden (TMB)_high (\u226510 Muts/Mb) was not correlated with any significant difference in OS compared with TMB_low (\u2264 10 Muts/Mb) measured in tissue samples (10.4 vs. 6.4 months, adjusted HR = 0.83) (Shao et al., 2020; 33119110). The impact of TMB on the prognosis and clinicopathological features of lung neuroendocrine cancers is unclear; large cell neuroendocrine carcinoma (LCNEC) cases with small cell lung cancer_like molecular features were reported to have significantly higher proliferative activity, as well as a trend toward better clinical benefit from treatment with chemotherapy, than non_small cell lung cancer_like tumors, but the average TMB was not significantly different between the two subsets of LCNEC (Rekhtman et al., 2016; 26960398). MCPyV_negative Merkel cell carcinoma (MCC), associated with higher TMB, has been reported to have a higher number of predicted tumor neoantigens and a significantly higher UV mutation signature than MCPyV_positive MCC (Harms et al., 2015; 26238782, Goh et al., 2016; 26655088). Within MCPyV_negative MCC tumors, the mutational burden has been reported to be significantly higher in PD_L1_positive tumors (more than 1% positive tumor and macrophage cells by immunohistochemistry) than in PD_L1_negative tumors (Wong et al., 2015; 26627015). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), and anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04237649", "Include": "true"}, {"nctId": "NCT03396445", "Include": "true"}, {"nctId": "NCT03530397", "Include": "true"}, {"nctId": "NCT03861793", "Include": "true"}, {"nctId": "NCT04047862", "Include": "true"}, {"nctId": "NCT04261439", "Include": "true"}, {"nctId": "NCT04892498", "Include": "true"}, {"nctId": "NCT04785196", "Include": "true"}, {"nctId": "NCT05113355", "Include": "true"}, {"nctId": "NCT05024214", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": [{"Name": "R130Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R130Q"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations have been reported across solid tumors including endometrial (31%), glioma (21%), thyroid (8.7%), melanoma (8.5%), head and neck carcinoma (6.5%) and colorectal (6.1%) (cbio_ Zehir et al., 2017; 28481359). Loss of heterozygosity of the genomic region that includes PTEN (10q23) has been reported in 53% (8/15) of pancreatic endocrine tumors, and in 80% (4/5) gastrointestinal neuroendocrine tumors (Perren et al., 2000; 11021813, Dacic et al., 2002; 12378519). Reports in the literature also associate PTEN mutation with neuroendocrine tumors (Jiao et al., 2011; 21252315, Van Gele et al., 2001; 11291079, Mussazhanova et al., 2013; 23844610). One study reported loss of Pten expression in 63% (17/27) of prostate small cell carcinomas, with 38% (5/13) displaying allelic loss (Tan et al., 2014; 24323898). Furthermore, one study reports that most of the 72 pancreatic endocrine tumors analyzed showed reduced PTEN expression (Missiaglia et al., 2010; 19917848). Loss of PTEN expression has been suggested to be associated with advanced tumor stage and shorter disease_free and overall survival in pancreatic NETs (Han et al., 2013; 23686804, Krausch et al., 2011; 22105477). Another study reported that low cytoplasmic PTEN expression is also associated with poor prognosis in pancreatic NETs (Missiaglia et al., 2010; 19917848). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04341259", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}]}}, {"Name": "Y29*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Y29*"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations have been reported across solid tumors including endometrial (31%), glioma (21%), thyroid (8.7%), melanoma (8.5%), head and neck carcinoma (6.5%) and colorectal (6.1%) (cbio_ Zehir et al., 2017; 28481359). Loss of heterozygosity of the genomic region that includes PTEN (10q23) has been reported in 53% (8/15) of pancreatic endocrine tumors, and in 80% (4/5) gastrointestinal neuroendocrine tumors (Perren et al., 2000; 11021813, Dacic et al., 2002; 12378519). Reports in the literature also associate PTEN mutation with neuroendocrine tumors (Jiao et al., 2011; 21252315, Van Gele et al., 2001; 11291079, Mussazhanova et al., 2013; 23844610). One study reported loss of Pten expression in 63% (17/27) of prostate small cell carcinomas, with 38% (5/13) displaying allelic loss (Tan et al., 2014; 24323898). Furthermore, one study reports that most of the 72 pancreatic endocrine tumors analyzed showed reduced PTEN expression (Missiaglia et al., 2010; 19917848). Loss of PTEN expression has been suggested to be associated with advanced tumor stage and shorter disease_free and overall survival in pancreatic NETs (Han et al., 2013; 23686804, Krausch et al., 2011; 22105477). Another study reported that low cytoplasmic PTEN expression is also associated with poor prognosis in pancreatic NETs (Missiaglia et al., 2010; 19917848). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04341259", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}]}}]}, "ReferenceLinks": null}, {"Name": "TSC1", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 2391+2T>C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 2391+2T>C"}}, "Interpretation": "TSC1 encodes the protein Hamartin, which interacts with Tuberin, the gene product of TSC2, to inhibit and regulate mTOR activity (Tee et al., 2003; 12906785, Inoki et al., 2003; 12869586). Alterations such as seen here may disrupt TSC1 function or expression (Miloloza et al., 2000; 10915759, Hoogeveen_Westerveld et al., 2010; 20547222, Hodges et al., 2001; 11741833). TSC1 mutations have been observed at varying frequency in neuroendocrine tumors, including 3.8% of pancreatic and 1.5% of lung neuroendocrine tumors, but have not ben observed in any of 212 small intestine, 23 large intestine, or 9 stomach neuroendocrine tumors analyzed in COSMIC (Apr 2022)(Tate et al., 2019; 30371878). In one study, low expression of TSC1 and TSC2 was more common in pancreatic neuroendocrine tumors (NET) than in small intestinal NET, however no correlation between TSC1 expression levels and overall survival was reported (Qian et al., 2013; 23980085). Published data investigating the prognostic implications of TSC1 alterations in neuroendocrine tumors are limited (PubMed, Nov 2021). In the scientific literature, there is speculation that neuroendocrine tumors may be a feature of tuberous sclerosis, caused by TSC1 and TSC2 mutations (Dworakowska D et al., 2009; 18978035, Starker L et al., 2009; 19125015, Arva N et al., 2012; 22173120). Loss or inactivation of TSC1 can activate mTOR signaling (Tee et al., 2003; 12906785, Mallela et al., 2021; 33575875); however, response rates for patients with TSC1_mutated solid tumors treated with MTOR inhibitors such as everolimus and temsirolimus have been low (Adib et al., 2021; 33727259, Nassar et al., 2020; 31653662, Voss et al., 2019; 30327302). In the prospective NCI_MATCH study, the ORR for patients with various TSC1_mutated solid tumors treated with everolimus was 7.7% (1/13); the single response was reported for a patient with urothelial cancer (Adib et al., 2021; 33727259). In TSC1_mutated renal cell carcinoma (RCC), although responses to MTOR inhibitors have been described in multiple case series and reports (Ali et al., 2015; 25796537, Lim et al., 2016; 26859683, Kwiatkowski et al., 2016; 26831717, Hamieh et al., 2018; 30256787, Roldan_Romero et al., 2020; 31335987), retrospective analysis of a broader cohort showed no responses in TSC1_mutated RCC (0/7) (Nassar et al., 2020; 31653662). Retrospective analyses of the RECORD_3, GRANITE_1, and EVOLVE_1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS (Voss et al., 2019; 30327302). PRs have been reported for patients with TSC1_altered perivascular epithelioid cell tumors (Wagner et al., 2021; 34637337, Kopparthy and Murphy, 2021; 34123648) and epithelial ovarian carcinoma (Dickson et al., 2021; ASCO Abstract 3111) treated with nab_sirolimus. Inactivating germline mutations in TSC1 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma (Gomez, 1991; 2039135, van Slegtenhorst et al., 1997; 9242607). TSC1 mutations account for approximately 10 to 30% of reported sporadic cases (Crino et al., 2006; 17005952). Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age (Curatolo et al., 2008; 18722871). In the appropriate clinical context, germline testing of TSC1 is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04185831", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "R882H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R882H"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Mutations at codon 882, including R882S, R882H, and R882C, have demonstrated reduced methyltransferase activity in vitro, with R882H and R882C conferring increased cell proliferation (Yan et al., 2011; 21399634, Holz_Schietinger et al., 2012; 22722925, Metzeler et al., 2012; 22124213). About half of all DNMT3A mutations in AML are R882H, which leads to a partially defective enzyme and altered oligomerization behavior, although the effect on global methylation remains to some extent controversial; in addition, at least one report suggests that mutation of R882 is associated with sensitivity to DNA methyltransferase inhibitors (reviewed in Abdel_Wahab and Levine, 2013; 23640996, Yan et al., 2011; 21399634, Metzeler et al., 2012; 22124213, Holz_Schietinger et al., 2012; 22722925). On the basis of this, any alteration at R882 is likely to promote tumorigenesis, although the efficacy of DNMT inhibitors may not be consistent for all mutations. DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GNAQ", "Include": "true", "Alterations": {"Alteration": {"Name": "R181T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R181T"}}, "Interpretation": "GNAQ encodes the protein guanine nucleotide_binding protein G(q) subunit alpha (Gq_alpha), a G protein that acts as a modulator of transmembrane signaling and activates phospholipase C (Dong et al., 1995; 8825633). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. GNAQ mutations have been reported in fewer than 1% of lung small cell carcinomas and have not been reported in any of the 15 ovary small cell carcinoma, 8 cervical small cell carcinoma, 1 cervical neuroendocrine carcinoma, or 1 head and neck neuroendocrine carcinoma samples analyzed in COSMIC (Jul 2022)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of GNAQ alterations in neuroendocrine cancers are limited (PubMed, Jul 2022). Preclinical studies have reported that tumors with GNAQ mutation may be sensitive to inhibitors of PKC or MEK, particularly MEK inhibitors in combination with other targeted agents (Mitsiades et al., 2011; 21828154, von Euw et al., 2012; 22515704, Wu et al., 2012; 22253748, Khalili et al., 2012; 22733540, Ho et al., 2012; 22808163). Clinical benefit has been observed in patients with uveal melanoma harboring GNA11 or GNAQ mutations treated with selumetinib (Carvajal et al., 2014; 24938562), although conflicting data have also been reported (Carvajal et al., 2018; 29528792). Phase 1 trials of single_agent PKC inhibitors sotrastaurin and IDE196 in metastatic uveal melanoma have yielded DCRs of 52.2% to 77.3% (Piperno_Neumann et al., 2020; 32029634, Kapiteijn et al., 2019; AACR Abstract CT068/25); treatment with sotrastaurin resulted in 4 PRs, with 1 PR observed in a patient harboring a GNAQ mutation (Piperno_Neumann et al., 2020; 32029634, Kapiteijn et al., 2019; AACR Abstract CT068/25). A preclinical study showed strong synergy between MEK and PKC inhibitors against melanoma cells harboring activating mutations in GNAQ or GNA11; the combined treatment, much more than treatment with either inhibitor alone, inhibited proliferation and induced apoptosis of melanoma cells in vitro and caused regression of uveal melanoma xenografts in vivo (Chen et al., 2013; 24141786). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R158P", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R158P"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutation has been reported in a number of carcinoid_endocrine cases, including 48% (15/31) of the stomach, 9.1% of large intestine, 6.8% of pancreatic, 5.8% of lung, and 4.8% of small intestine origin; TP53 mutations were also observed in 19% of Merkel cell carcinomas, 41% (9/22) of prostate small cell carcinomas, 14% (10/72) of cervical endocrine tumors, and 63% of small cell lung cancer samples (COSMIC, Jan 2022)(Tate et al., 2019; 30371878, Fernandez_Cuesta et al., 2014; 24670920, Higaki_Mori et al., 2012; 22795182, Rodig et al., 2012; 23114601, Takahashi et al., 1991; 1656362, Chen et al., 2012; 22389383, Wistuba et al., 1999; 9889022, Tan et al., 2014; 24323898, Yachida et al., 2012; 22251937). The frequency of TP53 mutation or loss and altered p53 levels in neuroendocrine lung tumors has been correlated with the degree of malignancy, as TP53 alterations are more frequent in the most malignant tumor types, including SCLC and large cell neuroendocrine carcinoma (Kobayashi et al., 2004; 15072592, Przygodzki et al., 1996; 8623922, Onuki et al., 1999; 10091733). Within neuroendocrine tumors, expression of p53 has been associated with aggressive and poorly differentiated gastroenteropancreatic neuroendocrine tumors and with shorter survival in patients with high_grade neuroendocrine carcinomas (O Toole et al., 2010; 20570957, Erler et al., 2011; 21058037, Liu et al., 2013; 23534765, Safatle_Ribeiro et al., 2007; 17206073). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Mutations in TP53 or RB1 are characteristic of poorly differentiated neuroendocrine carcinomas (NECs) (NCCN Neuroendocrine and Adrenal Tumors, v1.2022) (Pavel et al., 2020; 32272208, Baudin et al., 2021; 33482246, Rindi et al., 2018; 30140036, Nagtegaal et al., 2020; 31433515). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "London (United Kingdom), Colorado, Oklahoma, Texas, Pennsylvania, Tennessee, Florida", "NCTID": "NCT04657068", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "ATR Kinase Inhibitor VX_970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "California, Missouri, Pennsylvania, Massachusetts, Connecticut, Tennessee", "NCTID": "NCT02595931", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "ATR, TOP1", "Locations": "Arizona, Minnesota, Oklahoma, Pennsylvania, Connecticut, Tennessee, Florida", "NCTID": "NCT04514497", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Massachusetts, Maryland", "NCTID": "NCT04616534", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High_Grade Neuroendocrine Cancers", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "Maryland", "NCTID": "NCT04802174", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PD_L1", "Locations": "Texas", "NCTID": "NCT04266912", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "Q543*, Y215fs*17", "Title": "AZD6738 & Gemcitabine as Combination Therapy", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Cambridge (United Kingdom)", "NCTID": "NCT03669601", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "ADORA2A, CD73, PD_1", "Locations": "Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri", "NCTID": "NCT04237649", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "Safety and Pharmacokinetics Study of MK_5890 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Adults With Advanced Solid Tumors (MK_5890_001)", "StudyPhase": "PHASE 1", "Target": "PD_1, CD27", "Locations": "Taipei (Taiwan), Seoul (Korea, Republic of), Be er Sheva (Israel), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Madrid (Spain), Pozuelo de Alarcon (Spain), Santiago (Chile)", "NCTID": "NCT03396445", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_L1, PD_1, CTLA_4", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy)", "NCTID": "NCT03530397", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously_Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti_PD_1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY_2)", "StudyPhase": "PHASE 1/2", "Target": "PD_1", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Edmonton (Canada), Badalona (Spain), Rotterdam (Netherlands), Valencia (Spain), Madrid (Spain)", "NCTID": "NCT03861793", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TIGIT", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Guangdong (China), Changsha (China), Wuhan (China)", "NCTID": "NCT04047862", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas", "NCTID": "NCT04261439", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "Hypofractionated Radiotherapy Combined With PD_1 Inhibitor Sequential GM_CSF and IL_2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)", "StudyPhase": "PHASE 2", "Target": "PD_1", "Locations": "Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)", "NCTID": "NCT04892498", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "APG_115 in Combination With PD_1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, MDM2", "Locations": "Shanghai (China), Guangzhou (China)", "NCTID": "NCT04785196", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "Chidamide Plus Sintilimab for Chemotherapy_refractory Advanced High_grade Neuroendocrine Neoplasm", "StudyPhase": "PHASE 2", "Target": "HDAC, PD_1", "Locations": "Xiamen (China), Harbin (China)", "NCTID": "NCT05113355", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Blood Tumor Mutational Burden", "Alteration": "13", "Title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R", "Locations": "Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)", "NCTID": "NCT05024214", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)", "NCTID": "NCT04644068", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1", "Target": "AKTs", "Locations": "Shanghai City (China)", "NCTID": "NCT04341259", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee", "NCTID": "NCT04497116", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130QY29*", "Title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, Pol theta", "Locations": "London (United Kingdom), Oklahoma, New York, Pennsylvania, Tennessee, Texas, Florida", "NCTID": "NCT04991480", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, EGFR, ERBB4", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "A MolEcularly Guided Anti_Cancer Drug Off_Label Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, MEK, mTOR", "Locations": "Uppsala (Sweden), Gothenburg (Sweden)", "NCTID": "NCT04185831", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "splice site 2391+2T>C", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "1", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "2", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "3", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "4", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "5", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "6", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "7", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "8", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "9", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "10", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "11", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "12", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "13", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "14", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "15", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "16", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "17", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "18", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "19", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "20", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "21", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "22", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "23", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "24", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "25", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "26", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "27", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "28", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "29", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "30", "ReferenceId": "22274316", "FullCitation": "Katagiri A, et al. Int. J. Gynecol. Cancer (2012) pmid: 22274316", "Include": "true"}, {"number": "31", "ReferenceId": "23427874", "FullCitation": "Cho H, et al. Hum. Pathol. (2013) pmid: 23427874", "Include": "true"}, {"number": "32", "ReferenceId": "21822268", "FullCitation": "Gui Y, et al. Nat. Genet. (2011) pmid: 21822268", "Include": "true"}, {"number": "33", "ReferenceId": "23650517", "FullCitation": "Balb\u00e1s_Mart\u00ednez C, et al. PLoS ONE (2013) pmid: 23650517", "Include": "true"}, {"number": "34", "ReferenceId": "25175170", "FullCitation": "Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170", "Include": "true"}, {"number": "35", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "36", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "37", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "38", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "39", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "40", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "41", "ReferenceId": "21889920", "FullCitation": "Zhang X, et al. Cancer Epidemiol (2012) pmid: 21889920", "Include": "true"}, {"number": "42", "ReferenceId": "24430365", "FullCitation": "Zhao J, et al. Tumour Biol. (2014) pmid: 24430365", "Include": "true"}, {"number": "43", "ReferenceId": "23416164", "FullCitation": "Lichner Z, et al. Am. J. Pathol. (2013) pmid: 23416164", "Include": "true"}, {"number": "44", "ReferenceId": "33387086", "FullCitation": "Feng F, et al. Int J Clin Oncol (2021) pmid: 33387086", "Include": "true"}, {"number": "45", "ReferenceId": "32020551", "FullCitation": "Conci S, et al. Updates Surg (2020) pmid: 32020551", "Include": "true"}, {"number": "46", "ReferenceId": "29740198", "FullCitation": "Simbolo M, et al. Sci Rep (2018) pmid: 29740198", "Include": "true"}, {"number": "47", "ReferenceId": "26717940", "FullCitation": "Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940", "Include": "true"}, {"number": "48", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "49", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "50", "ReferenceId": "32568634", "FullCitation": "Yap TA, et al. J Clin Oncol (2020) pmid: 32568634", "Include": "true"}, {"number": "51", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "52", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "53", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "54", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "55", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "56", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "57", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "58", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "59", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "60", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "61", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "62", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "63", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "64", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "65", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "66", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "67", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "68", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "69", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "70", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "71", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "72", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "73", "ReferenceId": "26960398", "FullCitation": "Rekhtman N, et al. Clin. Cancer Res. (2016) pmid: 26960398", "Include": "true"}, {"number": "74", "ReferenceId": "26238782", "FullCitation": "Harms PW, et al. Cancer Res. (2015) pmid: 26238782", "Include": "true"}, {"number": "75", "ReferenceId": "26655088", "FullCitation": "Goh G, et al. Oncotarget (2016) pmid: 26655088", "Include": "true"}, {"number": "76", "ReferenceId": "26627015", "FullCitation": "Wong SQ, et al. Cancer Res. (2015) pmid: 26627015", "Include": "true"}, {"number": "77", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "78", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "79", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "80", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "81", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "82", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "83", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "84", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "85", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "86", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "87", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "88", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "89", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "90", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "91", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "92", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "93", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "94", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "95", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "96", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "97", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "98", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "99", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "100", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "101", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "102", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "103", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "104", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "105", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "106", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "107", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "108", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "109", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "110", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "111", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "112", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "113", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "114", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "115", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "116", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "117", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "118", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "119", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "120", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "121", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "122", "ReferenceId": "11021813", "FullCitation": "Perren A, et al. Am. J. Pathol. (2000) pmid: 11021813", "Include": "true"}, {"number": "123", "ReferenceId": "12378519", "FullCitation": "Dacic S, et al. Hum. Pathol. (2002) pmid: 12378519", "Include": "true"}, {"number": "124", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "125", "ReferenceId": "11291079", "FullCitation": "Van Gele M, et al. Int. J. Cancer (2001) pmid: 11291079", "Include": "true"}, {"number": "126", "ReferenceId": "23844610", "FullCitation": "Mussazhanova Z, et al. Thyroid (2014) pmid: 23844610", "Include": "true"}, {"number": "127", "ReferenceId": "24323898", "FullCitation": "Tan HL, et al. Clin. Cancer Res. (2014) pmid: 24323898", "Include": "true"}, {"number": "128", "ReferenceId": "19917848", "FullCitation": "Missiaglia E, et al. J. Clin. Oncol. (2010) pmid: 19917848", "Include": "true"}, {"number": "129", "ReferenceId": "23686804", "FullCitation": "Han X, et al. Tumour Biol. (2013) pmid: 23686804", "Include": "true"}, {"number": "130", "ReferenceId": "22105477", "FullCitation": "Krausch M, et al. Horm. Metab. Res. (2011) pmid: 22105477", "Include": "true"}, {"number": "131", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "132", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "133", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "134", "ReferenceId": "23582881", "FullCitation": "Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881", "Include": "true"}, {"number": "135", "ReferenceId": "34246347", "FullCitation": "Sweeney C, et al. Lancet (2021) pmid: 34246347", "Include": "true"}, {"number": "136", "ReferenceId": "30037818", "FullCitation": "de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818", "Include": "true"}, {"number": "137", "ReferenceId": "27872130", "FullCitation": "Saura C, et al. Cancer Discov (2017) pmid: 27872130", "Include": "true"}, {"number": "138", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "139", "ReferenceId": "27091708", "FullCitation": "Andr\u00e9 F, et al. J. Clin. Oncol. (2016) pmid: 27091708", "Include": "true"}, {"number": "140", "ReferenceId": "31841354", "FullCitation": "Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354", "Include": "true"}, {"number": "141", "ReferenceId": "30302599", "FullCitation": "Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599", "Include": "true"}, {"number": "142", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "143", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "144", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "145", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "146", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "147", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "148", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "149", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "150", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "151", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "152", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "153", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "154", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "155", "ReferenceId": "12906785", "FullCitation": "Tee AR, et al. Curr. Biol. (2003) pmid: 12906785", "Include": "true"}, {"number": "156", "ReferenceId": "12869586", "FullCitation": "Inoki K, et al. Genes Dev. (2003) pmid: 12869586", "Include": "true"}, {"number": "157", "ReferenceId": "10915759", "FullCitation": "Miloloza A, et al. Hum. Mol. Genet. (2000) pmid: 10915759", "Include": "true"}, {"number": "158", "ReferenceId": "20547222", "FullCitation": "Hoogeveen_Westerveld M, et al. Biochim. Biophys. Acta (2010) pmid: 20547222", "Include": "true"}, {"number": "159", "ReferenceId": "11741833", "FullCitation": "Hodges AK, et al. Hum. Mol. Genet. (2001) pmid: 11741833", "Include": "true"}, {"number": "160", "ReferenceId": "23980085", "FullCitation": "Qian ZR, et al. J. Clin. Oncol. (2013) pmid: 23980085", "Include": "true"}, {"number": "161", "ReferenceId": "18978035", "FullCitation": "Dworakowska D, et al. Endocr. Relat. Cancer (2009) pmid: 18978035", "Include": "true"}, {"number": "162", "ReferenceId": "19125015", "FullCitation": "Starker LF, et al. Curr Opin Oncol (2009) pmid: 19125015", "Include": "true"}, {"number": "163", "ReferenceId": "22173120", "FullCitation": "Arva NC, et al. Am. J. Surg. Pathol. (2012) pmid: 22173120", "Include": "true"}, {"number": "164", "ReferenceId": "33575875", "FullCitation": "Mallela K, et al. Mol Cell Biochem (2021) pmid: 33575875", "Include": "true"}, {"number": "165", "ReferenceId": "33727259", "FullCitation": "Adib E, et al. Clin Cancer Res (2021) pmid: 33727259", "Include": "true"}, {"number": "166", "ReferenceId": "31653662", "FullCitation": "Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662", "Include": "true"}, {"number": "167", "ReferenceId": "25796537", "FullCitation": "Ali SM, et al. Eur. Urol. (2015) pmid: 25796537", "Include": "true"}, {"number": "168", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "169", "ReferenceId": "26831717", "FullCitation": "Kwiatkowski DJ, et al. Clin. Cancer Res. (2016) pmid: 26831717", "Include": "true"}, {"number": "170", "ReferenceId": "30256787", "FullCitation": "Hamieh L, et al. PLoS Genet (2018) pmid: 30256787", "Include": "true"}, {"number": "171", "ReferenceId": "31335987", "FullCitation": "Roldan_Romero JM, et al. Int J Cancer (2020) pmid: 31335987", "Include": "true"}, {"number": "172", "ReferenceId": "34637337", "FullCitation": "Wagner AJ, et al. J Clin Oncol (2021) pmid: 34637337", "Include": "true"}, {"number": "173", "ReferenceId": "34123648", "FullCitation": "Kopparthy P, et al. Cureus (2021) pmid: 34123648", "Include": "true"}, {"number": "174", "ReferenceId": "2039135", "FullCitation": "Ann. N. Y. Acad. Sci. (1991) pmid: 2039135", "Include": "true"}, {"number": "175", "ReferenceId": "9242607", "FullCitation": "van Slegtenhorst M, et al. Science (1997) pmid: 9242607", "Include": "true"}, {"number": "176", "ReferenceId": "17005952", "FullCitation": "Crino PB, et al. N. Engl. J. Med. (2006) pmid: 17005952", "Include": "true"}, {"number": "177", "ReferenceId": "18722871", "FullCitation": "Curatolo P, et al. Lancet (2008) pmid: 18722871", "Include": "true"}, {"number": "178", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "179", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "180", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "181", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "182", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "183", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "184", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "185", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "186", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "187", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "188", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "189", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "190", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "191", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "192", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "193", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "194", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "195", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "196", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "197", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "198", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "199", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "200", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "201", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "202", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "203", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "204", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "205", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "206", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "207", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "208", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "209", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "210", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "211", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "212", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "213", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "214", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "215", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "216", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "217", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "218", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "219", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "220", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "221", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "222", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "223", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "224", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "225", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "226", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "227", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "228", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "229", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "230", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "231", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "232", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "233", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "234", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "235", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "236", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "237", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "238", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "239", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "240", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "241", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "242", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "243", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "244", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "245", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "246", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "247", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "248", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "249", "ReferenceId": "21399634", "FullCitation": "Yan XJ, et al. Nat. Genet. (2011) pmid: 21399634", "Include": "true"}, {"number": "250", "ReferenceId": "22722925", "FullCitation": "Holz_Schietinger C, et al. J. Biol. Chem. (2012) pmid: 22722925", "Include": "true"}, {"number": "251", "ReferenceId": "22124213", "FullCitation": "Metzeler KH, et al. Leukemia (2012) pmid: 22124213", "Include": "true"}, {"number": "252", "ReferenceId": "23640996", "FullCitation": "Abdel_Wahab O, et al. Blood (2013) pmid: 23640996", "Include": "true"}, {"number": "253", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "254", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "255", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "256", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "257", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "258", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "259", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "260", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "261", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "262", "ReferenceId": "8825633", "FullCitation": "Dong Q, et al. Genomics (1995) pmid: 8825633", "Include": "true"}, {"number": "263", "ReferenceId": "21828154", "FullCitation": "Mitsiades N, et al. Invest. Ophthalmol. Vis. Sci. (2011) pmid: 21828154", "Include": "true"}, {"number": "264", "ReferenceId": "22515704", "FullCitation": "von Euw E, et al. Mol. Cancer (2012) pmid: 22515704", "Include": "true"}, {"number": "265", "ReferenceId": "22253748", "FullCitation": "Wu X, et al. PLoS ONE (2012) pmid: 22253748", "Include": "true"}, {"number": "266", "ReferenceId": "22733540", "FullCitation": "Khalili JS, et al. Clin. Cancer Res. (2012) pmid: 22733540", "Include": "true"}, {"number": "267", "ReferenceId": "22808163", "FullCitation": "Ho AL, et al. PLoS ONE (2012) pmid: 22808163", "Include": "true"}, {"number": "268", "ReferenceId": "24938562", "FullCitation": "Carvajal RD, et al. JAMA (2014) pmid: 24938562", "Include": "true"}, {"number": "269", "ReferenceId": "29528792", "FullCitation": "Carvajal RD, et al. J. Clin. Oncol. (2018) pmid: 29528792", "Include": "true"}, {"number": "270", "ReferenceId": "32029634", "FullCitation": "Piperno_Neumann S, et al. Mol. Cancer Ther. (2020) pmid: 32029634", "Include": "true"}, {"number": "271", "ReferenceId": "24141786", "FullCitation": "Chen X, et al. Oncogene (2014) pmid: 24141786", "Include": "true"}, {"number": "272", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "273", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "274", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "275", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "276", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "277", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "278", "ReferenceId": "24670920", "FullCitation": "Fernandez_Cuesta L, et al. Nat Commun (2014) pmid: 24670920", "Include": "true"}, {"number": "279", "ReferenceId": "22795182", "FullCitation": "Higaki_Mori H, et al. Hum. Pathol. (2012) pmid: 22795182", "Include": "true"}, {"number": "280", "ReferenceId": "23114601", "FullCitation": "Rodig SJ, et al. J. Clin. Invest. (2012) pmid: 23114601", "Include": "true"}, {"number": "281", "ReferenceId": "1656362", "FullCitation": "Takahashi T, et al. Oncogene (1991) pmid: 1656362", "Include": "true"}, {"number": "282", "ReferenceId": "22389383", "FullCitation": "Chen H, et al. Endocr. Relat. Cancer (2012) pmid: 22389383", "Include": "true"}, {"number": "283", "ReferenceId": "9889022", "FullCitation": "Wistuba II, et al. Gynecol. Oncol. (1999) pmid: 9889022", "Include": "true"}, {"number": "284", "ReferenceId": "22251937", "FullCitation": "Yachida S, et al. Am. J. Surg. Pathol. (2012) pmid: 22251937", "Include": "true"}, {"number": "285", "ReferenceId": "15072592", "FullCitation": "Kobayashi Y, et al. Cancer Sci. (2004) pmid: 15072592", "Include": "true"}, {"number": "286", "ReferenceId": "8623922", "FullCitation": "Przygodzki RM, et al. Am. J. Pathol. (1996) pmid: 8623922", "Include": "true"}, {"number": "287", "ReferenceId": "10091733", "FullCitation": "Onuki N, et al. Cancer (1999) pmid: 10091733", "Include": "true"}, {"number": "288", "ReferenceId": "20570957", "FullCitation": "O Toole D, et al. Endocr. Relat. Cancer (2010) pmid: 20570957", "Include": "true"}, {"number": "289", "ReferenceId": "21058037", "FullCitation": "Erler BS, et al. Tumour Biol. (2011) pmid: 21058037", "Include": "true"}, {"number": "290", "ReferenceId": "23534765", "FullCitation": "Liu SZ, et al. Asian Pac. J. Cancer Prev. (2013) pmid: 23534765", "Include": "true"}, {"number": "291", "ReferenceId": "17206073", "FullCitation": "Safatle_Ribeiro AV, et al. Eur J Gastroenterol Hepatol (2007) pmid: 17206073", "Include": "true"}, {"number": "292", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "293", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "294", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "295", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "296", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "297", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "298", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "299", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "300", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "301", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "302", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "303", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "304", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "305", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "306", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "307", "ReferenceId": "32272208", "FullCitation": "Pavel M, et al. Ann Oncol (2020) pmid: 32272208", "Include": "true"}, {"number": "308", "ReferenceId": "33482246", "FullCitation": "Baudin E, et al. Ann Oncol (2021) pmid: 33482246", "Include": "true"}, {"number": "309", "ReferenceId": "30140036", "FullCitation": "Rindi G, et al. Mod Pathol (2018) pmid: 30140036", "Include": "true"}, {"number": "310", "ReferenceId": "31433515", "FullCitation": "Nagtegaal ID, et al. Histopathology (2020) pmid: 31433515", "Include": "true"}, {"number": "311", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "312", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "313", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "314", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "315", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "316", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "317", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_10_04 20:28:08", "OpName": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "13 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "57%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary undifferentiated neuroendocrine carcinoma", "flowcell_analysis": "2000023778", "gender": "female", "pathology_diagnosis": "Neuroendocrine Cancer (please correlate with genomics)", "pipeline_version": "v3.14.0", "purity_assessment": "73.0", "specimen": "ORD_1462448_01*US1401552.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1462448_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1401552.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0036", "cds_effect": "87T>G", "depth": "2241", "equivocal": "false", "functional_effect": "nonsense", "gene": "PTEN", "percent_reads": "0.36", "position": "chr10:89653789", "protein_effect": "Y29*", "status": "likely", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0038", "cds_effect": "4319C>A", "depth": "6078", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "0.38", "position": "chr5:112175610", "protein_effect": "P1440Q", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.4796", "cds_effect": "833C>T", "depth": "1176", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "47.96", "position": "chr2:29917835", "protein_effect": "P278L", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0416", "cds_effect": "2391+2T>C", "depth": "577", "equivocal": "false", "functional_effect": "splice", "gene": "TSC1", "percent_reads": "4.16", "position": "chr9:135777990", "protein_effect": "splice site 2391+2T>C", "status": "likely", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0054", "cds_effect": "2296T>C", "depth": "1672", "equivocal": "false", "functional_effect": "missense", "gene": "POLD1", "percent_reads": "0.54", "position": "chr19:50917044", "protein_effect": "S766P", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5918", "cds_effect": "986C>T", "depth": "147", "equivocal": "false", "functional_effect": "missense", "gene": "REL", "percent_reads": "59.18", "position": "chr2:61147581", "protein_effect": "P329L", "status": "unknown", "strand": "+", "transcript": "NM_002908", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.1019", "cds_effect": "3885_3887delTCT", "depth": "1334", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "CREBBP", "percent_reads": "10.19", "position": "chr16:3795304", "protein_effect": "L1296del", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.046", "cds_effect": "115G>A", "depth": "2281", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "4.6", "position": "chr10:89653817", "protein_effect": "A39T", "status": "unknown", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0254", "cds_effect": "389G>A", "depth": "3311", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "2.54", "position": "chr10:89692905", "protein_effect": "R130Q", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0077", "cds_effect": "473G>C", "depth": "5199", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "0.77", "position": "chr17:7578457", "protein_effect": "R158P", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0583", "cds_effect": "3566G>T", "depth": "841", "equivocal": "false", "functional_effect": "missense", "gene": "SMARCA4", "percent_reads": "5.83", "position": "chr19:11143985", "protein_effect": "R1189L", "status": "unknown", "strand": "+", "transcript": "NM_003072", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5261", "cds_effect": "2276G>A", "depth": "1838", "equivocal": "false", "functional_effect": "missense", "gene": "LTK", "percent_reads": "52.61", "position": "chr15:41796610", "protein_effect": "C759Y", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.8064", "cds_effect": "1348G>A", "depth": "878", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "80.64", "position": "chrX:39933251", "protein_effect": "V450I", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0768", "cds_effect": "1486G>A", "depth": "2838", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "7.68", "position": "chrX:66766474", "protein_effect": "D496N", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.003", "cds_effect": "1225A>G", "depth": "1644", "equivocal": "false", "functional_effect": "missense", "gene": "KEAP1", "percent_reads": "0.3", "position": "chr19:10602353", "protein_effect": "M409V", "status": "unknown", "strand": "_", "transcript": "NM_012289", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0153", "cds_effect": "2645G>A", "depth": "1439", "equivocal": "false", "functional_effect": "missense", "gene": "DNMT3A", "percent_reads": "1.53", "position": "chr2:25457242", "protein_effect": "R882H", "status": "known", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0021", "cds_effect": "3295A>G", "depth": "3329", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "0.21", "position": "chr17:29559188", "protein_effect": "K1099E", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5272", "cds_effect": "642delC", "depth": "423", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "52.72", "position": "chr1:27023535", "protein_effect": "Y215fs*17", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5083", "cds_effect": "2075C>T", "depth": "1078", "equivocal": "false", "functional_effect": "missense", "gene": "POLD1", "percent_reads": "50.83", "position": "chr19:50912844", "protein_effect": "A692V", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0861", "cds_effect": "1276A>G", "depth": "848", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "8.61", "position": "chr5:56161779", "protein_effect": "T426A", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.1178", "cds_effect": "710delG", "depth": "1690", "equivocal": "false", "functional_effect": "frameshift", "gene": "POLD1", "percent_reads": "11.78", "position": "chr19:50905581", "protein_effect": "G237fs*39", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0207", "cds_effect": "542G>C", "depth": "2992", "equivocal": "false", "functional_effect": "missense", "gene": "GNAQ", "percent_reads": "2.07", "position": "chr9:80412499", "protein_effect": "R181T", "status": "known", "strand": "_", "transcript": "NM_002072", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.4852", "cds_effect": "1370_1372delAGG", "depth": "1348", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "DAXX", "percent_reads": "48.52", "position": "chr6:33287880", "protein_effect": "E457del", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.1156", "cds_effect": "1627C>T", "depth": "848", "equivocal": "false", "functional_effect": "nonsense", "gene": "ARID1A", "percent_reads": "11.56", "position": "chr1:27057919", "protein_effect": "Q543*", "status": "known", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0311", "cds_effect": "2873A>G", "depth": "2958", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "3.11", "position": "chr3:178948101", "protein_effect": "Q958R", "status": "unknown", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0013", "cds_effect": "3239A>G", "depth": "5424", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "0.13", "position": "chr11:108143534", "protein_effect": "D1080G", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0024", "cds_effect": "1655T>G", "depth": "2888", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "0.24", "position": "chr17:29548881", "protein_effect": "L552R", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0026", "cds_effect": "5023A>G", "depth": "4571", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA1", "percent_reads": "0.26", "position": "chr17:41219676", "protein_effect": "T1675A", "status": "unknown", "strand": "_", "transcript": "NM_007294", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5084", "cds_effect": "631G>A", "depth": "1243", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "50.84", "position": "chr1:156838353", "protein_effect": "V211M", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.0018", "cds_effect": "6622C>T", "depth": "4548", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "0.18", "position": "chr11:108196086", "protein_effect": "H2208Y", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"allele_fraction": "0.5539", "cds_effect": "3017C>G", "depth": "1596", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "55.39", "position": "chr11:76255610", "protein_effect": "P1006R", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "12.64", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HHV_4", "reads_per_million": "33", "status": "unknown", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"organism": "HHV_8", "reads_per_million": "15", "status": "unknown", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}, {"organism": "HPV_16", "reads_per_million": "19", "status": "unknown", "dna_evidence": {"sample": "SQ_US1401552.01_1"}}]}}}}}